HGF and cancer: While subtype I and II CAFs have high HGF and FGF7 expressions and protect cancer cells by activating tyrosine kinase receptor-mediated signaling, subtype III CAFs are associated with better clinical response and immune cell migration via the production of chemoattractants for immune cells with enhanced migration of tumor-infiltrating lymphocytes.